KR20210101205A - 아미노산 화합물 및 사용 방법 - Google Patents

아미노산 화합물 및 사용 방법 Download PDF

Info

Publication number
KR20210101205A
KR20210101205A KR1020217013781A KR20217013781A KR20210101205A KR 20210101205 A KR20210101205 A KR 20210101205A KR 1020217013781 A KR1020217013781 A KR 1020217013781A KR 20217013781 A KR20217013781 A KR 20217013781A KR 20210101205 A KR20210101205 A KR 20210101205A
Authority
KR
South Korea
Prior art keywords
tetrahydro
naphthyridin
ethyl
homoserine
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217013781A
Other languages
English (en)
Korean (ko)
Inventor
제이컵 차
마누엘 무노즈
모린 라일리
니콜 쿠퍼
캐터리나 레프테리스
데이빗 제이. 모건스 주니어
티모시 홈
야준 정
Original Assignee
플라이언트 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플라이언트 테라퓨틱스, 인크. filed Critical 플라이언트 테라퓨틱스, 인크.
Publication of KR20210101205A publication Critical patent/KR20210101205A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217013781A 2018-10-08 2019-10-08 아미노산 화합물 및 사용 방법 Ceased KR20210101205A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862742901P 2018-10-08 2018-10-08
US62/742,901 2018-10-08
PCT/US2019/055252 WO2020076862A1 (en) 2018-10-08 2019-10-08 Amino acid compounds and methods of use

Publications (1)

Publication Number Publication Date
KR20210101205A true KR20210101205A (ko) 2021-08-18

Family

ID=70051340

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013781A Ceased KR20210101205A (ko) 2018-10-08 2019-10-08 아미노산 화합물 및 사용 방법

Country Status (23)

Country Link
US (3) US11180494B2 (enExample)
EP (1) EP3863711A4 (enExample)
JP (1) JP7523450B2 (enExample)
KR (1) KR20210101205A (enExample)
CN (1) CN113195053B (enExample)
AU (1) AU2019358041A1 (enExample)
BR (1) BR112021006620A2 (enExample)
CA (1) CA3115643A1 (enExample)
CL (2) CL2021000863A1 (enExample)
CO (1) CO2021004279A2 (enExample)
CR (1) CR20210224A (enExample)
CU (1) CU24690B1 (enExample)
DO (1) DOP2021000054A (enExample)
EA (1) EA202190967A1 (enExample)
EC (1) ECSP21032717A (enExample)
IL (1) IL282026A (enExample)
JO (1) JOP20210056A1 (enExample)
MX (1) MX2021004015A (enExample)
PE (1) PE20211463A1 (enExample)
PH (1) PH12021550784A1 (enExample)
SG (1) SG11202103283RA (enExample)
TW (1) TW202028179A (enExample)
WO (1) WO2020076862A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
TW202028179A (zh) * 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
WO2024145245A2 (en) * 2022-12-27 2024-07-04 Pliant Therapeutics, Inc. Alpha-v-beta-8 integrin inhibitors and uses thereof
GB202301024D0 (en) * 2023-01-24 2023-03-08 Univ Bradford Compounds
CN122270455A (zh) * 2023-12-22 2026-06-23 北京炫景瑞医药科技有限公司 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
KR20100037600A (ko) 2007-06-13 2010-04-09 브리스톨-마이어스 스큅 컴퍼니 응고 인자 억제제로서의 디펩티드 유사체
US20120289481A1 (en) * 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
LT3275883T (lt) 2015-03-25 2021-08-25 Fujifilm Corporation Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba
KR20190026001A (ko) 2016-07-05 2019-03-12 더 락커펠러 유니버시티 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
US10538542B2 (en) 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) * 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료

Also Published As

Publication number Publication date
CA3115643A1 (en) 2020-04-16
CO2021004279A2 (es) 2021-04-30
AU2019358041A1 (en) 2021-05-20
US11952376B2 (en) 2024-04-09
US20200109141A1 (en) 2020-04-09
CL2021000863A1 (es) 2021-09-10
CN113195053B (zh) 2024-08-30
PH12021550784A1 (en) 2021-10-25
US20220144829A1 (en) 2022-05-12
EP3863711A4 (en) 2022-07-06
EP3863711A1 (en) 2021-08-18
CN113195053A (zh) 2021-07-30
SG11202103283RA (en) 2021-04-29
DOP2021000054A (es) 2021-08-31
MX2021004015A (es) 2021-06-23
IL282026A (en) 2021-05-31
WO2020076862A1 (en) 2020-04-16
JOP20210056A1 (ar) 2021-03-24
CL2023001331A1 (es) 2023-10-20
ECSP21032717A (es) 2021-06-30
CU20210027A7 (es) 2021-11-04
JP7523450B2 (ja) 2024-07-26
US20240270742A1 (en) 2024-08-15
BR112021006620A2 (pt) 2021-07-06
TW202028179A (zh) 2020-08-01
EA202190967A1 (ru) 2021-09-17
JP2022508657A (ja) 2022-01-19
PE20211463A1 (es) 2021-08-05
CR20210224A (es) 2021-06-08
US11180494B2 (en) 2021-11-23
CU24690B1 (es) 2023-12-07

Similar Documents

Publication Publication Date Title
JP7523450B2 (ja) アミノ酸化合物およびその使用方法
JP7425757B2 (ja) 非分岐リンカーを伴うアミノ酸化合物およびその使用方法
KR102787602B1 (ko) 아미노산 화합물 및 사용 방법
WO2020210404A1 (en) Dosage forms and regimens for amino acid compounds
CA3042710A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
EP3558303A1 (en) Amino acid compounds and methods of use
AU2022265730A1 (en) Expanded dosage regimens for integrin inhibitors
AU2024348597A1 (en) 3-phenylpropylamine derivative
BR122023025996A2 (pt) Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção
HK40049583A (en) Amino acid compounds with unbranched linkers and methods of use
HK40057175A (en) Amino acid compounds and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210507

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221007

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240816

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250325

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D